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Abstract:  The effects of crude polysaccharide from Purslane (CPP) on body weight 
(bw), blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), 
triglyceride (TG) and serum insulin levels were studied in diabetes mellitus mice. CPP 
treatment (200, 400 mg/kg bw) for 28 days resulted in a significant decrease in the 
concentrations of fasting blood glucose (FBG), TC and TG. Furthermore, CPP 
significantly increased the concentration of HDL-c, body weight and serum insulin level 
in the mice. In addition, according to acute toxicity studies and single cell gel 
electrophoresis analysis, CPP did not produce any physical or behavioral signs of 
toxicity. More significantly, our data demonstrated CPP exhibited the best effects at the 
dose of 400 mg/kg bw. The above results suggest that CPP can control blood glucose and 
modulate the metabolism of glucose and blood lipids in diabetes mellitus mice, so we 
conclude that CPP should be evaluated as a candidate for future studies on   
diabetes mellitus.  
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1. Introduction  
 
Purslane (Little Hogweed; Chinese name: Ma-Chi-Xian) is a grassy plant with small yellow 
flowers and stems sometimes flushed red or purple, which grows widely in different areas of the world 
including the north of China [1,2]. The plant contains many biologically active compounds, including 
free oxalic acids, alkaloids, omega-3 fatty acids, coumarins, flavonoids, cardiac glycosides, and 
anthraquinone glycosides [3,4]. Purslane is considered a type of common weed, but it can be eaten as 
a potherb without any side effects. Moreover, Purslane is known in folk medicine in some parts of 
China as a hypotensive and antidiabetic [5,6,7]. Though there is no scientific evidence to support the 
antidiabetic effects of Purslane, people continue to use it in the treatment of this condition. The 
objective of this study was to extract crude polysaccharide(s) from Purslane and assess the 
hypoglycemic effects of these constituents with animal tests for the use of this plant in the treatment  
of diabetes. 
 
2. Results and Discussion 
 
2.1. Acute toxicity studies 
 
Acute toxicity studies revealed no obvious symptom of toxicity of CPP or any significant changes 
in general behavior in mice. There was no lethality or any toxic reactions found at any of the doses 
selected through the end of the study period. 
 
2.2. Effect of CPP on body weight in mice 
 
Alloxan-induced diabetic mice exhibited loss of body weight [8,9]. Before embarking on the 
experiments, all the groups had no significant difference in body weight (P >0.05) (Table 1).  
Table 1. Effect of CPP on body weight (g) in mice. 
Group 
Number 
of 
animals 
Days after dosing
0d 7d  14d  21d  28d 
NC 8  18.99±0.60  23.45±0.57  25.39±0.57  27.56±0.57  30.22±0.85 
DC 8  19.14±0.75  20.65±0.74*  22.40±1.06*  23.40±0.99*  24.41±1.51* 
DLCPP 8 19.15±1.14  20.97±1.44*  22.93±1.53*  25.47±1.07*#  26.90±0.96*# 
DHCPP 8 19.49±0.74  21.50±1.29*  23.51±0.95*#  26.01±0.65*#  27.62±1.13*# 
DGLI 8  19.08±1.07  22.62±1.52#  24.97±0.98#  26.91±0.99#  29.18±1.05# 
n=8; (mean±S.D., g); * P < 0.05 as compared with normal control group (NC).# P < 0.05 as compared 
with diabetic control group (DC). DLCPP = diabetic mice+ low dose CPP; DHCPP = diabetic mice + 
high dose CPP; DGLI = diabetic mice + glibencamide. 
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A significant (P < 0.05) decrease in body weight was detected in the DC, DLCPP and DHCPP 
groups as compared to the normal control group from 7 days after alloxan injection. However, the 
body weights in the DHCPP group were significantly (P < 0.05) and dose-dependently increased as 
compared to those of the diabetic control from 14 days after administration. In the DGLI group, a 
significant (P < 0.05) increase in body weight as compared to the DC group was also detected from 7 
days after administration. The results are shown in Table 1.The present study showed that the body 
weight was significantly decreased in the diabetic control group as compared to the normal control 
group within 28 days. However, the treatment with CPP for 28 days improved the body weight loss. 
 
2.3. Effect of CPP on fasting blood glucose levels in mice 
 
Effective control of the blood glucose level is a key step in preventing or reversing diabetic 
complications and improving the quality of life in both Type 1 and Type 2 diabetic patients [10,11]. 
The alloxan-induced diabetic mice exhibited hyperglycemia. In the diabetic groups, a significant (P< 
0.05) increase in FBG was detected, as compared to the normal control group, but these abnormal 
increases in blood glucose levels significantly (P < 0.05) and dose-dependently decreased in the CPP -
administered groups as compared to the diabetic control group from 7 days after administration. On the 
28th day, blood glucose levels in the DLCPP and DHCPP groups had decreased by 36.0% and 62.9%, 
respectively. In the DGLI group, the decrease was also significant (P  < 0.05) from 7 days after 
administration. The NC and DC groups did not show any significant variation on the blood glucose 
level throughout the experimental period (p > 0.05). The results are shown in Table 2. 
 
Table 2. Effect of CPP on blood glucose Level (mmol/L ) in mice. 
Groups 
Number 
of 
animals 
Days after dosing (day) 
0 7  14  21 28 
NC 8  5.15±0.  0.17  5.14±0.17  5.10±0.13  5.04±0.08  5.16±0.10 
DC 8  15.36±0.39*  15.33±0.26*  15.33±0.35*  15.15±0.15*  15.23±0.29* 
DLCPP 8 15.25±0.30*  12.67±0.24*#  11.29±0.28*#  10.56±0.32*#  9.76±0.29*# 
DHCPP 8 15.39±0.28*  11.92±0.26*#  10.48±0.30*#  9.47±0.29*#  8.33±0.17*# 
DGLI 8  15.29±0.29*  9.06±0.14*#  7.24±0.21*#  6.47±0.24*#  5.68±0.33*# 
n=8; (mean±S.D., g); * P < 0.05 as compared with normal control group.;# P < 0.05 as compared with 
diabetic control group. 
 
The present study showed that alloxan-induced diabetic mice presented obvious hyperglycemic 
symptoms, but CPP produces a significant antihyperglycemic effect when administered orally to 
alloxan-diabetic mice. The dosage of 400mg/kg is more effective than that of 200 mg/kg. 
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2.4. Effect of CPP on blood lipids levels in mice  
 
Diabetes mellitus is usually complicated with hyperlipoproteinemia. The present results showed 
that the TC and TG levels were significantly elevated in the diabetic control group as compared to the 
normal control group (P < 0.05), and serum HDL-c level, a friendly lipoprotein, was decreased in 
diabetic control group as compared to the normal control group (P < 0.05). After supplementation with 
CPP and glibenclamide, the alteration in lipid metabolism was partially attenuated as evidenced by 
decreased serum TG and TC levels and by increased HDL-c concentration in diabetic mice. The 
response was better in the DHCPP group compared to the DLCPP group which is comparable to that 
of the DGLI group. The results are shown in Table 3. 
 
Table 3. Effect of CPP on blood lipids (mmol/L ) in mice. 
Groups 
Number of 
animals 
TG TC  HDL-c 
NC 8  1.64±0.02  2.70±0.02  1.64±0.01 
DC 8 2.05±0.04*  3.34±0.04*  0.77±0.02* 
DLCPP 8  1.86±0.02*#  3.16±0.02*#  0.84±0.02*# 
DHCPP 8  1.77±0.02*#  3.12±0.02*#  1.11±0.03*# 
DGLI 8  1.72±0.01*#  3.03±0.05*#  1.39±0.02*# 
n=8; (mean±S.D., g);*P<0.05 as compared with normal control group (NC); 
#P<0.05 as compared with diabetic control group. 
 
The serum TC and TG were decreased significantly in diabetic mice after CPP supplementation. 
These effects may be due to low activity of cholesterol biosynthesis enzymes or low level of lipolysis 
which are under the control of insulin [12]. 
 
2.5. Effect of CPP on blood serum insulin levels in mice 
 
Serum insulin levels of the normal control group were higher than those of the diabetic control 
group, which indicated that alloxan damaged the pancreas islet cells. After 28 days of the CPP 
supplementation to the mice, there was a significant elevation in serum insulin level as compared to 
the diabetic control group ( p < 0.05), which implied that treatment with CPP improved the insulin 
secretion on diabetic mice. In the DHCPP group, the insulin level was higher than that of the DLCPP 
group. The results implied that CPP improved the function of islet cells and stimulated the insulin 
secretion. The results are shown in Figure 1. 
Alloxan could damage pancreatic β cells, resulting in a decrease in endogenous insulin secretion, 
which decreased utilization of glucose by the tissues consequently. In this study, we have observed 
that CPP increased the concentration of serum insulin in alloxan-induced diabetic mice. The possible 
mechanism of action of CPP could be correlated with promoting insulin secretion by closure of K
+-
ATP channels, membrane depolarization and stimulation of Ca
2+ influx, an initial key step in insulin 
secretion[13]. Additional studies are needed to address this hypothesis. Int. J. Mol. Sci. 2009, 10                 
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Figure 1. Effect of CPP on serum insulin level in mice. 
0
1
2
3
4
5
6
7
8
9
10
11
12
*
S
e
r
u
m
 
i
n
s
u
l
i
n
 
l
e
v
e
l
 
(
u
U
/
m
l
)
                        NC                 DC             DLCPP        DHCPP           
  
*
*
 
*P<0.05 as compared with diabetic control group. 
 
3. Experimental Section 
 
3.1. Plant materials 
 
Purslane was collected in Sichuan Province in July and the material was identified by Mr. Wang 
Guang-Yao, a botanist from the Jilin Agriculture Science and Technology College. A voucher 
specimen has been deposited in the herbarium of the Jilin Agriculture Science and Technology 
College. Fresh and intact Purslane dried in the shade was chosen as experimental material. 
 
3.2. Drugs and reagents 
 
Alloxan was purchased from Sigma Co. (USA). Glucose Analyzer and strips were purchased from 
Roche Diagnostic Co. (USA). Reagents for total cholesterol (TC), triglyceride (TG), high-density 
lipoprotein cholesterol (HDL-c) were obtained from Beijing Chengxinde Biochemistry Reagent 
Company (Beijing, P.R. China). Reagents for serum insulin was purchased from Adlitteram Diagnostic 
Laboratories Co. (USA). 
 
3.3. Preparation of crude polysaccharide from Purslane (CPP) 
 
The shade dried Purslane was crushed in an electrical grinder and then powdered, 1,000 g of this 
powder was immersed in tenfold dH2O and boiled at 100 °C for 9 h [14-16], and then the water extract 
was collected. The process was repeated, and the extracts were combined and concentrated on a 
vacuum rotary evaporator at 60 °C. The concentrated solution was precipitated by addition of four 
times its volume of volume 80% ethanol and the precipitate was washed in turn with 100 % ethanol, 
100 % ether and acetone. Crude polysaccharide from Purslane (CPP) was obtained by vacuum drying Int. J. Mol. Sci. 2009, 10                 
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[14,15]. A Unico-7200 spectrophotometer (Unico Co., Shanghai, P.R. China) was used to determine 
the content of polysaccharides in the above extracted product at 490 nm [15,16]. The polysaccharide 
content was calculated using the following linear equation based on the calibration curve:  
Y = 3.809 ×10
-2 +1.321X, r = 0.9998 
where Y is the absorbance and X is the polysaccharide content.  
 
3.4. Animals and diets 
 
Male mice of original Kun-ming strain, approximately 18 to 22 g, were obtained from the Animal 
Department of Beijing Institute of Traditional Medical and Pharmaceutical Sciences. The animals were 
housed in a room maintained at 22 °C to 25 °C with relative air humidity of 50 % to 70 % controlled 
room under a 12 h light-dark cycle, and basal diet and water were supplied ad libitum. Approval of this 
experiment was obtained from the Institutional Animal Ethics Committee of XiChang College . 
 
3.5. Preparation of diabetic mice 
 
Male mice were adapted to diet for 1 week before the experiment began [16]. After a 14 h fasting, 
mice were induced with a single injection of 4 % alloxan prepared freshly at a dose of 200 mg/kg bw 
[11,12]. Diabetes was confirmed by the determination of tail vein blood glucose levels on the third day 
after administration of alloxan. Mice having blood glucose levels greater than 11.1 mmol/L were 
considered diabetic and used for the study. 
 
3.6. Experimental design  
 
Portulaca oleracea L. polysaccharide (CPP) and glibenclamide (Glib) were dissolved in distilled 
water and were fed by gavage to mice once a day. Forty male mice were randomly divided into five 
equal groups as follows [17-20]: 
i)   Normal control group (NC): normal control mice administered water daily for 28 days; 
ii)  Diabetic control group (DC): diabetic control mice administered water daily for 28 days;  
iii)   Diabetic + CPP (200 mg/kg) group (DLCPP): diabetic mice administered CPP (200 mg/kg) 
daily for 28 days; 
iv)   Diabetic + CPP (400 mg/kg) group (DHCPP): diabetic mice administered CPP (400 mg/kg) 
daily for 28 days;  
v)  Diabetic + glibenclamide (4 mg/kg) group (DGLI): diabetic mice administered reference drug 
Glib (4 mg/kg) daily for 28 days.  
Animals of control group, NC and DC groups were subjected to forceful feeding of 0.5 mL distilled 
water/100 g bw daily for 28 days to keep all the animals at same type of treatment condition in respect 
to CPP supplemented groups.  
On the starting day, fasting blood glucose (FBG) was monitored of all the animals in each group. 
On the 28th day of the experiment, the mice were sacrificed by decapitation under light ether Int. J. Mol. Sci. 2009, 10                 
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anesthesia and blood was collected from dorsal aorta and serum was separated by centrifugation for 
5min and was kept at -20 °C for the biochemical assay of total cholesterol (TC), high-density 
lipoprotein cholesterol (HDLc), triglyceride (TG) and for serum insulin assay. TC, TG, and HDL-c 
were determined by enzyme methods; Serum insulin level was estimated by insulin-ELISA kit 
according to the manufacturer’s instruction. 
 
3.7. Testing of fasting blood glucose (FBG)  
 
During the CPP supplement for 28 days, fasting blood glucose level was measured for once every 
week. Blood was collected from tip of the tail vein and fasting blood glucose level was measured by 
using a glucose analyzer. At the same time, the body weight of each mouse was measured by balance. 
 
3.8. Acute toxicity studies  
 
Healthy mice (18–22 g) of either sex, starved overnight were divided into three groups (n=6) and 
were orally fed with CPP in increasing dose levels of 250, 500, 750 and 1,000 mg/kg bw The animals 
were observed continuously for 2 h under the following profiles [21]: 
i)   Behavioral profile. Alertness, restlessness, irritability, and fearfulness. 
ii)  Neurological profile. Spontaneous activity, reactivity, touch response, pain response and gait. 
iii)  Autonomic profile. Defecation and urination. 
After a period of 24 and 72 h they were observed for any lethality or death. 
 
3.9. Statistical analysis  
 
All results were expressed as mean ± SD and were analyzed by SPSS for Windows, version 13.0 
(SPSS Inc, Chicago). The Duncan test and one way analysis of variance were used for 
comparisons[22,23]. The values were considered significant when P < 0.05. 
 
4. Conclusions  
 
Our research has indicated that CPP possesses antidiabetic activities and the dose of 400 mg/kg bw 
represents the optimal level for effecting a positive diabetic response in mice. Therefore, CPP should 
be considered as a candidate for future studies on diabetes. Although, in this test, the main 
pharmacological ingredient of CPP is polysaccharide, the further studies are in progress to clarify 
antidiabetic activity of the other compounds and to elucidate the molecular and cellular mechanism  
of CPP. 
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